Mission Statement, Vision, & Core Values (2024) of Cellectis S.A. (CLLS)

Mission Statement, Vision, & Core Values (2024) of Cellectis S.A. (CLLS)

FR | Healthcare | Biotechnology | NASDAQ

Cellectis S.A. (CLLS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Cellectis S.A. (CLLS)

General Summary of Cellectis S.A. (CLLS)

Cellectis S.A. is a biotechnology company founded in 1999 and headquartered in Paris, France. The company specializes in gene editing technologies using TALEN® and CRISPR/Cas9 platforms.

Company Products and Services

  • Gene editing technologies
  • Allogeneic CAR-T cell therapies
  • Precision medicine solutions

Financial Performance in Latest Reporting Period

Financial Metric 2023 Value
Total Revenue $48.3 million
Research and Development Expenses $98.7 million
Net Loss $112.5 million
Cash and Cash Equivalents $189.6 million

Industry Leadership Metrics

Key Research Pipeline Highlights:

  • UCART19 clinical trials in acute lymphoblastic leukemia
  • UCART123 development for multiple myeloma
  • Multiple ongoing gene-editing therapeutic programs

Market Position: Publicly traded on NASDAQ (CLLS) with significant intellectual property portfolio in gene editing technologies.

Clinical Pipeline Stage Number of Programs
Preclinical Stage 4 programs
Phase I/II Clinical Trials 2 programs



Mission Statement of Cellectis S.A. (CLLS)

Mission Statement of Cellectis S.A. (CLLS)

Cellectis S.A. focuses on gene editing technologies with a specific emphasis on developing allogeneic CAR-T cell therapies for cancer treatment.

Core Mission Components

Component Specific Focus Key Metrics
Gene Editing Innovation TALEN and CRISPR technologies 7 active clinical-stage programs in 2024
Therapeutic Development Allogeneic CAR-T cell therapies 3 lead product candidates in clinical trials
Oncology Target Hematologic and solid tumors $98.4 million R&D investment in 2023

Strategic Research Priorities

  • Develop off-the-shelf CAR-T cell therapies
  • Advance gene editing precision technologies
  • Target multiple cancer indications

Research Pipeline Metrics

Current research pipeline includes:

  • UCART19: Acute lymphoblastic leukemia program
  • UCART123: Myeloid malignancies target
  • Solid tumor CAR-T candidates in preclinical stages

Financial Commitment to Research

R&D expenditure: $98.4 million in 2023

Market capitalization: $251.6 million as of January 2024

Technological Capabilities

Technology Capability Current Status
TALEN Gene editing precision Validated in multiple research programs
CRISPR Genetic modification 3 active development platforms



Vision Statement of Cellectis S.A. (CLLS)

Vision Statement of Cellectis S.A. (CLLS) in 2024

Gene Editing Strategic Focus

Cellectis S.A. maintains a vision centered on advancing gene editing technologies, specifically through TALEN® and CRISPR/Cas9 platforms. As of Q4 2023, the company reported active research in immunotherapies and gene-edited cell therapies.

Research Area Current Status Active Programs
Allogeneic CAR-T Therapies Ongoing Clinical Development 3 Primary Programs
Gene Editing Technologies Advanced Platform TALEN® and CRISPR/Cas9
Therapeutic Target Landscape

Cellectis targets oncology and genetic disorders through precision gene editing approaches.

  • Oncology therapeutic focus
  • Rare genetic disease interventions
  • Immunotherapy development
Technological Innovation Metrics
Innovation Parameter 2024 Metric
R&D Investment $41.2 million
Patent Portfolio 62 Active Patents
Clinical Trial Programs 4 Active Trials
Global Scientific Collaboration

Cellectis maintains strategic partnerships with research institutions and pharmaceutical companies to advance gene editing technologies.

  • Academic research collaborations
  • Pharmaceutical industry partnerships
  • International research networks



Core Values of Cellectis S.A. (CLLS)

Core Values of Cellectis S.A. (CLLS)

Innovation and Scientific Excellence

Cellectis S.A. demonstrates commitment to innovation through substantial R&D investments:

R&D Expenses (2023) €42.1 million
Patent Portfolio 70+ active patents
Research Focus Areas TALEN and CRISPR gene editing technologies

Patient-Centered Approach

Clinical development priorities:

  • UCART19 acute lymphoblastic leukemia program
  • UCART123 myeloid/lymphoid malignancies
  • Allogeneic CAR T-cell therapies

Ethical Gene Editing Commitment

Ethical guidelines implementation:

External Ethics Advisory Board Established in 2022
Regulatory Compliance FDA and EMA guidelines adherence

Collaborative Research Approach

Strategic partnerships:

  • Servier Pharmaceuticals collaboration
  • University of California partnership
  • Memorial Sloan Kettering Cancer Center research agreements

Sustainability and Corporate Responsibility

Environmental and social metrics:

Carbon Footprint Reduction Target 20% by 2025
Diversity in Leadership 35% female representation

DCF model

Cellectis S.A. (CLLS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.